References
- Vilanova JC, Baleato-Gonzalez S, Romero MJ, Carrascoso-Arranz J, Luna A. Assessment of musculoskeletal malignancies with functional MR imaging. Magn Reson Imaging Clin N Am. 2016; 24: 239–59. DOI: 10.1016/j.mric.2015.08.006
- Garner HW, Kransdorf MJ. Musculoskeletal sarcoma: Update on imaging of the post-treatment patient. Can Assoc Radiol J. 2016; 67: 12–20. DOI: 10.1016/j.carj.2014.11.002
- Garner HW, Kransdorf MJ, Peterson JJ. Posttherapy imaging of musculoskeletal neoplasms. Radiol Clin North Am. 2011; 49: 1307–23. DOI: 10.1016/j.rcl.2011.07.011
- Fayad LM, Jacobs MA, Wang X, Carrino JA, Bluemke DA. Musculoskeletal tumors: How to use anatomic, functional, and metabolic MR techniques. Radiology. 2012; 265: 340–56. DOI: 10.1148/radiol.12111740
- Winfield JM, Miah AB, Strauss D, et al. Utility of multi-parametric quantitative magnetic resonance imaging for characterization and radiotherapy response assessment in soft-tissue sarcomas and correlation with histopathology. Front Oncol. 2019; 9. DOI: 10.3389/fonc.2019.00280
- Park MY, Jee W-H, Kim SK, Lee S-Y, Jung J-Y. Preliminary experience using dynamic MRI at 3.0 Tesla for evaluation of soft tissue tumors. Korean J Radiol. 2013; 14: 102–9. DOI: 10.3348/kjr.2013.14.1.102
- Tuncbilek N, Karakas HM, Okten OO. Dynamic contrast enhanced MRI in the differential diagnosis of soft tissue tumors. Eur J Radiol. 2005; 53: 500–5. DOI: 10.1016/j.ejrad.2004.04.012
- van Rijswijk CS, Geirnaerdt MJ, Hogendoorn PC, et al. Soft-tissue tumors: Value of static and dynamic gadopentetate dimeglumine–enhanced MR imaging in prediction of malignancy. Radiology. 2004; 233: 493–502. DOI: 10.1148/radiol.2332031110
- Del Grande F, Subhawong T, Weber K, Aro M, Mugera C, Fayad LM. Detection of soft-tissue sarcoma recurrence: added value of functional MR imaging techniques at 3.0 T. Radiology. 2014; 271: 499–511. DOI: 10.1148/radiol.13130844
- Costa FM, Canella C, Gasparetto E. Advanced magnetic resonance imaging techniques in the evaluation of musculoskeletal tumors. Radiol Clin North Am. 2011; 49: 1325–58. DOI: 10.1016/j.rcl.2011.07.014
- Gruber L, Loizides A, Luger AK, et al. Soft-tissue tumor contrast enhancement patterns: Diagnostic value and comparison between ultrasound and MRI. AJR Am J Roentgenol. 2017; 208: 393–401. DOI: 10.2214/AJR.16.16859
- Hirschmann A, van Praag VM, Haas RL, van de Sande MA, Bloem JL. Can we use MRI to detect clinically silent recurrent soft-tissue sarcoma? Eur Radiol. 2020; 30: 4724–33. DOI: 10.1007/s00330-020-06810-z
- Gandon Y, Olivie D, Guyader D, et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet. 2004; 363: 357–62. DOI: 10.1016/S0140-6736(04)15436-6
- Zhang YZ, Shen Y, Wang LF, Ding WY, Xu JX, He J. Magnetic resonance T2 image signal intensity ratio and clinical manifestation predict prognosis after surgical intervention for cervical spondylotic myelopathy. Spine (Phila Pa 1976). 2010; 35: E396–9. DOI: 10.1097/BRS.0b013e3181c6dbc4
- Wang LF, Zhang YZ, Shen Y, et al. Using the T2-weighted magnetic resonance imaging signal intensity ratio and clinical manifestations to assess the prognosis of patients with cervical ossification of the posterior longitudinal ligament. J Neurosurg Spine. 2010; 13: 319–23. DOI: 10.3171/2010.3.SPINE09887
- Verstraete KL, Lang P. Bone and soft tissue tumors: The role of contrast agents for MR imaging. Eur J Radiol. 2000; 34: 229–46. DOI: 10.1016/S0720-048X(00)00202-3
- Renne SL. Who, how and what of pathology of soft tissue sarcoma. Chin Clin Oncol. 2021; 10: 53. DOI: 10.21037/cco.2018.10.09
- Jackson A, Li K-L, Zhu X. Semi-quantitative parameter analysis of DCE-MRI revisited: Monte-Carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis. PLOS ONE. 2014; 9:
e90300 . DOI: 10.1371/journal.pone.0090300
